Background: Acute ischemic stroke (AIS) is closely related to the level of inflammatory factors. This study aimed to explore the correlation between interleukin-6 (IL-6), interleukin-8 (IL-8), and the modified early warning score (MEWS) of AIS patients and their condition and prognosis.
Methods:The clinical data of 95 AIS patients admitted to our hospital from January 2019 to October 2019 were selected, and 91 cases were finally recruited to the study group according to the inclusion and exclusion criteria. A control group was recruited comprising 70 healthy patients. The differences in IL-6 and IL-8 levels between the 2 groups were compared. Multiple logistic regression analysis was used to analyze the independent risk factors affecting the prognosis of AIS patients. A receiver-operating characteristic (ROC) curve was used to analyze the predictive value of IL-6, IL-8, and MEWS for the poor prognosis of AIS patients.Results: The levels of IL-6 and IL-8 in the study group were higher than those of the control group (P<0.05). After 90 days of treatment, 69 cases in the study group allocated into the good prognosis group, and 22 were allocated into the poor prognosis group. The National Institutes of Health Stroke Scale (NIHSS) scores before thrombolysis, blood glucose before thrombolysis, systolic blood pressure 2 h after thrombolysis, IL-6, IL-8, and MEWS scores within 24 h of admission in the good prognosis group were lower than those of the poor prognosis group (P<0.05). The area under the curve (AUC) of IL-6, IL-8, MEWS, and the 3 combined curves were 0.937, 0.897, 0.839, and 0.976, respectively, and the area under the combined detection curve was the largest.
Conclusions:The inflammatory response and secondary brain damage after AIS are influenced by IL-6 and IL-8. Combined with the MEWS score, IL-6 and IL-8 can be used as important indicators to judge the severity of the early condition of AIS patients. The combination of these 3 indicators has high accuracy in evaluating the prognosis of patients and is worthy of clinical promotion.